Report cover image

Global Biosimilars Market (2022 Edition) – Analysis By Product Type, Application, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2023-2028)

Publisher Azoth Analytics
Published Aug 31, 2022
Length 180 Pages
SKU # AZAN17372208

Description

Global Biosimilars Market (2022 Edition) – Analysis By Product Type, Application, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2023-2028)

Executive Summary

The Global Biosimilars Market was valued at USD 16.48 Billion in the year 2021 with the Europe region leading the regional market share. One of the main factors driving this market is the expiration of patents of major pharmaceutical drugs and thus the opportunity to develop more biosimilar drugs.

Additionally, Biosimilars are priced way lower than their reference counterparts, with the increasing burden of health expenditure. Biosimilars provide relief to the healthcare infrastructure of several developing countries and are anticipated to impel market growth in the forecast period.

The Asia Pacific is the fastest growing market in the biosimilars market as countries within the region are providing opportunities to grow and sell medicines. The growing initiatives of the government and increasing investment in healthcare are providing rapid growth.

The FDA reported the shortage of drugs during COVID-19 due to a lack of API and disruptions in the supply chain market. The higher rate of competition in the biosimilar market led to the growth of biologics having long-term supplies. A longer time for approvals was occurring due to a delay in the inspection of the manufacturing facility. The delivery of products is also the major concern impacting the market of biosimilars apart from product manufacturing.

Scope of the Report
  • The report presents the analysis of Biosimilars Market for the historical period of 2018-2021, estimates for 2022 and the forecast period of 2023-2028.
  • The report analyses the Biosimilars Market by Value (USD Million).
  • The report analyses the Biosimilars Market by Product Type (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin Others).
  • The report analyses the Biosimilars Market by Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases, Others).
  • The Global Biosimilars Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
  • The Global Biosimilars Market has been analysed By Country (United States, Canada, Germany, U.K, France, Italy, Spain, China, Japan, India).
  • The key insights of the report have been presented through the leading company shares. Also, the attractiveness of the market has been presented by region, by Product Type and by End User.
  • Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
  • The report tracks competitive developments, strategies, and recent developments. The companies analysed in the report include Pfizer, Dr.Reddy's Laboratories, Amgen, Novartis AG, Teva Pharmaceuticals Ltd., Samsung Biologics, Eli lilly and company, Stada Arzneimittel, Celltrion, Biocon Limited.
Key Target Audience
  • Biosimilar Companies
  • Pharmaceutical and Healthcare Companies
  • End Users (Hospitals, Ambulatory Surgical Centres, Research & Laboratories)
  • Research and Development (R&D) Organizations
  • Government Bodies & Regulating Authorities
  • Investment Banks and Equity Firms

Table of Contents

180 Pages
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Global Biosimilars Market: Product Overview
4. Global Biosimilars Market: An Analysis
4.1 Assessment of Macro Economic Indicators of Global Biosimilars Market
Table 1: Global GDP per capita (2018-2020) In USD Thousands
Table 2: Global Aged Population (Above 65), 2017-21 (% of total Population)
Table 3: Global Aged Population(Above 65), By Country, 2021 (% of total Population, roundoff)
Table 4: Global Medical Spending in 2020, By Region, (% of Total)
Table 5: Global Prevalence of Cardiovascular Diseases, (in million), 2015-2019
Table 6: Current Healthcare Expenditure (% Share of GDP), By Selected Country, 2016-2020 (In %)
Table 7: Global Expected Healthcare Industry Outlook
Table 8: Regional Expected Healthcare Industry Growth Rate By Year 2024
4.2 Global Biosimilars Market, Market Size, By Value, 2018-2028
Table 9: Global Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
4.3 Global Biosimilars Market: Growth and Forecast
4.4 Impact of COVID-19 on Global Biosimilars Market
5. Global Biosimilars Market: Segment Analysis
5.1 Global Biosimilars Market Segmentation, By Product Type
5.2 Competitive Positioning of Biosimilars Market: By Product Type (2021 & 2028)
Table 10: Global Biosimilars Market- By Product Type Market Share, 2021 & 2028
5.3 By Monoclonal antibodies, By Value (USD Billion), 2018-2028
Table 11: Global Biosimilars Market- By Product Type, By Monoclonal antibodies, By Value (USD Billion), 2018-2028
5.4 By Filgrastim and Pegfilgrastim, By value (USD Billion), 2018-2028
Table 12: Global Biosimilars Market- By Product Type, By Filgrastin and Pegfilgrastin, By Value (USD Billion), 2018-2028
5.5 By Insulin, By value (USD Billion), 2018-2028
Table 13: Global Biosimilars Market- By Product Type, By Insulin, By Value (USD Billion), 2018-2028
5.6 By Others, By value (USD Billion), 2018-2028
Table 14: Global Biosimilars Market- By Product Type, By Others, By Value (USD Billion), 2018-2028
6. Global Biosimilars Market: Segment Analysis
6.1 Global Biosimilars Market Segmentation, By Application
6.2 Competitive Positioning of Global Biosimilars Market, By Application (2021 & 2028)
Table 15: Global Biosimilars Market - By Application Market Share, 2021 & 2028
6.3 By Oncology, By value (USD Billion), 2018-2028
Table 16: Global Biosimilars Market- By Application, By Oncology, By Value (USD Billion), 2018-2028
6.4 By Chronic and Autoimmune Diseases, By Value (USD Billion), 2018-2028
Table 17: Global Biosimilars Market- By Application, By Chronic and Auto-immune diseases, By Value (USD Billion), 2018-2028
6.5 By Blood Disorders, By value (USD Billion), 2018-2028
Table 18: Global Biosimilars Market- By Application, By Blood Diseases, By Value (USD Billion), 2018-2028
6.6 By Infectious Diseases , By Value (USD Billion), 2018-2028
Table 19: Global Biosimilars Market- By Application, By Infectious diseases, By Value (USD Billion), 2018-2028
6.7 By Others, By value (USD Billion), 2018-2028
Table 20: Global Biosimilars Market- By Application, By Others, By Value (USD Billion), 2018-2028
7. Global Biosimilars Market: Regional Analysis
7.1 Competitive Positioning of Global Biosimilars Market: By Region (2021 & 2028)
Table 21: Global Biosimilars Market- By Region Market Share, 2021 & 2028
8. Americas Biosimilars Market: An Analysis (2018-2028)
8.1 Assessment of Macro Economic Indicators of Americas Biosimilars Market
Table 22: Americas Population (in Millions), 2018-2021
Table 23: North America Population ages 65 and above (% of total Population), 2017-21
Table 24: Latin America & Caribbean Population ages 65 and above (% of total Population), 2017-21
Table 25: Current health expenditure per capita in the U.S. and Canada (current USD), 2020
Table 26: Prevalence of Cardiovascular Diseases in Americas, (in million), 2015-2019
Table 27: Americas Diabetes Prevalence, By Country, 2021 (in million)
Table 28: Prevalence of Cancer in the Region of Americas(In Millions), 2015-2019
8.2 Americas Biosimilars Market- Size and Forecast, By Value (2018-2028)
Table 29: Americas Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
8.3 Americas Biosimilars Market: Prominent Companies
8.4 Americas Biosimilars Market: Segment Analysis
8.5 Americas Biosimilars Market By Product Type (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin and Others)
Table 30: Americas Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
8.6 Americas Biosimilars Market By Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases and Others)
Table 31: Americas Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
8.7 Americas Biosimilars Market: Country Analysis
8.8 Market Opportunity Chart of Americas Biosimilars Market - By Country, By Value (Year-2028)
Table 32: Market Opportunity Chart of Americas Biosimilars Market- By Country, By Value (Year-2028)
8.9 Competitive Positioning of Americas Biosimilars Market - By Country
Table 33: Americas Biosimilars Market- By Country Market Share, 2021 & 2028
8.10 United States Biosimilars Market: Size and Forecast, By Value (2018-2028)
Table 34: United States Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
8.11 United States Biosimilars Market By Product Type and By Application, By Value (2018-2028)
Table 35: United States Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Table 36: United States Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
8.12 Canada Biosimilars Market: Size and Forecast, By Value (2018-2028)
Table 37: Canada Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
8.13 Canada Biosimilars Market By Product Type and By Application, By Value (2018-2028)
Table 38: Canada Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Table 39: Canada Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
9. Europe Biosimilars Market: An Analysis (2018-2028)
9.1 Assessment of Macro Economic Indicators of Asia Pacific Biosimilars Market
Table 40: European Union Population (in Millions), 2018-2021
Table 41: Population ages 65 and above(% of total Population) in European Countries, 2020
Table 42: European Union Current health expenditure per capita (current USD), 2015-19
Table 43: Country wise healthcare expenditure in Europe (% of GDP), 2020
Table 44: European Union GDP Per Capita, value (USD Billion), 2018-20
Table 45: Europe Prevalence of Cancer (in Million), 2015-2019
Table 46: Europe Diabetes Prevalence, By Country, 2021 (in million)
9.2 Europe Biosimilars Market- Size and Forecast, By Value (2018-2028)
Table 47: Europe Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
9.3 Europe Biosimilars Market: Prominent Companies
9.4 Europe Biosimilars Market: Segment Analysis
9.5 Europe Biosimilars Market By Product Type (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin and Others), By Value, 2018-2028
Table 48: Europe Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
9.6 Europe Biosimilars Market By Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases and Others), By Value, 2018-2028
Table 49: Europe Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
9.7 Europe Biosimilars Market: Country Analysis
9.8 Market Opportunity Chart of Europe Biosimilars Market - By Country, By Value (Year-2028)
Table 50: Market Opportunity Chart of Europe Biosimilars Market- By Country, By Value (Year-2028)
9.9 Competitive Positioning of Europe Biosimilars Market - By Country
Table 51: Europe Biosimilars Market- By Country Market Share, 2021 & 2028
9.10 Italy Biosimilars Market: Size and Forecast, By Value (2018-2028)
Table 52: Italy Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
9.11 Italy Biosimilars Market By Product Type and By Application, By Value (2018-2028)
Table 53: Italy Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Table 54: Italy Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
9.12 Germany Biosimilars Market: Size and Forecast, By Value (2018-2028)
Table 55: Germany Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
9.13 Germany Biosimilars Market By Product Type and By Application, By Value (2018-2028)
Table 56: Germany Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Table 57: Germany Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
9.14 France Biosimilars Market: Size and Forecast, By Value (2018-2028)
Table 58: France Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
9.15 France Biosimilars Market By Product Type and By Application, By Value (2018-2028)
Table 59: France Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Table 60: France Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
9.16 United Kingdom Biosimilars Market: Size and Forecast, By Value (2018-2028)
Table 61: United Kingdom Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
9.17 United Kingdom Biosimilars Market By Product Type and By Application, By Value (2018-2028)
Table 62: United Kingdom Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Table 63: United Kingdom Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
9.18 Spain Biosimilars Market: Size and Forecast, By Value (2018-2028)
Table 64: Spain Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
9.19 Spain Biosimilars Market By Product Type and By Application, By Value (2018-2028)
Table 65: Spain Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Table 66: Spain Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
10. Asia Pacific Biosimilars Market: An Analysis (2018-2028)
10.1 Assessment of Macro Economic Indicators of Asia Pacific Biosimilars Market
Table 67: Asia Pacific, Population ages 65 and above (% of total Population), 2016-20
Table 68: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
Table 69: Asia Pacific Current health expenditure per capita (current USD), 2014-18
Table 70: Asia Pacific, Current health expenditure per capita, by countries (current USD), 2019
Table 71: East Asia and Pacific Population (in Billion), 2018-2020
Table 72: Prevalence of Total Cancer in Asia, (in million), 2015-2019
Table 73: Asia Pacific Diabetes Prevalence, By Country, 2020 (% of Population Age 20 to 79)
10.2 Asia Pacific Biosimilars Market- Size and Forecast, By Value (2018-2028)
Table 74: Asia Pacific Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
10.3 Asia Pacific Biosimilars Market: Prominent Companies
10.4 Asia Pacific Biosimilars Market: Segment Analysis
10.5 Asia Pacific Biosimilars Market By Product Type, (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin and Others)
Table 75: Asia Pacific Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
10.6 Asia Pacific Biosimilars Market By Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases and Others), By Value
Table 76: Asia Pacific Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
10.7 Asia Pacific Biosimilars Market: Country Analysis
10.8 Market Opportunity Chart of Asia Pacific Biosimilars Market - By Country, By Value (Year-2028)
Table 77: Market Opportunity Chart of Europe Biosimilars Market- By Country, By Value (Year-2028)
10.9 Competitive Positioning of Asia Pacific Biosimilars Market - By Country
Table 78: Asia Pacific Biosimilars Market- By Country Market Share, 2021 & 2028
10.10 China Biosimilars Market: Size and Forecast, By Value (2018-2028)
Table 79: China Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
10.11 China Biosimilars Market By Product Type and By Application, By Value (2018-2028)
Table 80: China Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Table 81: China Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
10.12 Japan Biosimilars Market: Size and Forecast, By Value (2018-2028)
Table 82: Japan Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
10.13 Japan Biosimilars Market By Product Type and By Application, By Value (2018-2028)
Table 83: Japan Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Table 84: Japan Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
10.14 India Biosimilars Market: Size and Forecast, By Value (2018-2028)
Table 85: India Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
10.15 India Biosimilars Market By Product Type and By Application, By Value (2018-2028)
Table 86: India Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Table 87: India Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
11. MEA Biosimilars Market
11.1 Assessment of Macro Economic Indicators of MEA Biosimilars Market
Table 88: Middle East and North Africa Population (in Million), 2018-2020
Table 89: Middle East & North Africa , Current health expenditure per capita (current USD), 2016-19
Table 90: Prevalence of Cancer in Middle East & North Africa, (in million), 2015-2019
Table 91: Middle East & North Africa , Current health expenditure per capita (% of GDP), 2016-19
11.2 MEA Biosimilars Market- Size and Forecast, By Value (2018-2028)
Table 92: MEA Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
11.3 MEA Biosimilars Market By Product Type, (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin and Others)
Table 93: MEA Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
11.4 MEA Biosimilars Market By Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases and Others), By Value
Table 94: MEA Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
12. Global Biosimilars Market Dynamics
12.1 Global Biosimilars Market Drivers
12.2 Global Biosimilars Market Restraints
12.3 Global Biosimilars Market Trends
13. Market Attractiveness and Strategic Analysis
13.1 Market Attractiveness Chart of Global Biosimilars Market - By Product Type (Year 2028)
Table 95: Market Attractiveness Chart of Global Biosimilars Market- By Product Type (Year-2028)
13.2 Market Attractiveness Chart of Global Biosimilars Market - By Application (Year 2028)
Table 96: Market Attractiveness Chart of Global Biosimilars Market- By Application (Year-2028)
13.3 Market Attractiveness Chart of Global Biosimilars Market - By Region (Year 2028)
Table 97: Market Attractiveness Chart of Global Biosimilars Market- By Region (Year-2028)
14. Competitive Landscape
14.1 Market Share of global leading companies
Table 98: Global Biosimilars Market Share (%), 2021
14.2 Recent Developments and Mergers & Acquisitions
15. Company Profiles (Business Description, Financial Analysis, Business Strategy)
15.1 Pfizer
Table 99: Pfizer Limited, Sales Revenues, 2018-2021 (USD Billion)
Table 100: Pfizer Limited, Net Earnings, 2018-2021 (USD Billion)
Table 101: Pfizer Limited, By Business Segment (%), FY2021
Table 102: Pfizer Limited, By Geographical Segment (%), FY2021
15.2 Dr.Reddy's Laboratories
Table 103: Dr. Reddyís Laboratories Sales Revenues, 2018-2021 (USD Billion)
Table 104: Dr. Reddyís Laboratories Net Earnings, 2018-2021 (USD Billion)
Table 105: Dr. Reddyís Laboratories, By Business Segment (%), FY2021
Table 106: Dr. Reddyís Laboratories, By Business Segment (%), FY2020
15.3 Amgen
Table 107: Amgen Corporation Annual Sales Revenue, 2018-2021 (USD Million)
Table 108: Amgen Corporation Net Earnings, 2018-2021 (USD Million)
Table 109: Amgen Net Sales Revenue, By Business Segment (%), FY2021
Table 110: Amgen Sales Revenue, By Geographic Segment (%), FY2021
15.4 Novartis AG
Table 111: Novartis AG Annual Sales Revenue, 2018-2021 (USD Million)
Table 112: Novartis AG Net Earnings, 2018-2021 (USD Million)
Table 113: Novartis AG Sales Revenue, By Business Segment (%), FY2021
Table 114: Novartis AG Sales Revenue, By Geographical Segment (%), FY2021
15.5 Teva Pharmaceuticals Ltd.
Table 115: Teva Pharmaceuticals Ltd., Annual Sales Revenue, 2018-2021 (USD Million)
Table 116: Teva Pharmaceuticals Ltd., Net Earnings, 2018-2021 (USD Million)
Table 117: Teva Pharmaceuticals Ltd., Sales Revenue, By Business Segment (%), FY2021
Table 118: Teva Pharmaceuticals Ltd., Sales Revenue, By Geographical Segment (%), FY2021
15.6 Samsung Biologics
Table 119: Samsung Biologics, Annual Sales Revenue, 2018-2021 (USD Million)
Table 120: Samsung Biologics, Net Earnings, 2018-2021 (USD Million)
Table 121: Samsung Biologics, Sales Revenue, By Business Segment (%), FY2021
Table 122: Samsung Biologics, Sales Revenue, By Geographic Segment (%), FY2021
15.7 Eli lilly and company
Table 123: Eli Lilly and company, Annual Sales Revenue, 2018-2021 (USD Million)
Table 124: Eli Lilly and company, Net Earnings, 2018-2021 (USD Million)
Table 125: Eli Lilly and company, Sales Revenue, By Business Segment (%), FY2021
Table 126: Eli Lilly and company, Sales Revenue, By Geographic Segment (%), FY2021
15.8 Stada Arzneimittel
Table 127: Stada Arzneimittel AG Annual Sales Revenue, 2018-2021 (USD Million)
Table 128: Stada Arzneimittel AG Net Earnings, 2018-2021 (USD Million)
Table 129: Stada Arzneimittel AG Sales Revenue, By Business Segment (%), FY2021
Table 120: Stada Arzneimittel AG Sales Revenue, By Geographical Segment (%), FY2021
15.9 Celltrion
Table 131: Celltrion, Annual Sales Revenue, 2018-2021 (USD Billion)
Table 132: Celltrion, Net Profit, 2018-2021 (USD Billion)
15.10 Biocon Limited
Table 133: Biocon Limited, Annual Sales Revenue (USD Million), 2018-2021
Table 134: Biocon Limited, Annual Net Earnings (USD Million), 2018-2021
Table 135: Biocon Limited, Sales Revenue, By Business Segment (%), FY2021
Table 136: Biocon Limited, Sales Revenue, By Geographical Segment (%), FY2021

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us